伊立替康联合氟尿嘧啶/亚叶酸钙方案一线治疗37例晚期大肠癌

背景与目的：伊立替康联合氟尿嘧啶／亚叶酸钙方案为晚期大肠癌一线治疗的标准方案。本研究观察伊立替康联合氟尿嘧啶／亚叶酸钙双周（CPT—11＋5FU／LV双周FOLFIRI）方案一线治疗晚期大肠癌的客观有效率及不良反应。方法：2001年5月-2005年3月，37例晚期大肠癌患者接受FOLFIRI方案一线治疗。化疗剂量为CPT—11 180mg／m^2静脉点滴第1天，亚叶酸钙（LV）200mg／m^2静脉点滴第1、2天，5．FU400mg／m^2静推第1、2天，5-FU600mg／m^2持续泵注44小时第1、2天，14天为1周期。结果：36例可评价疗效患者有效率为41。7％。Ⅲ／Ⅳ度骨髓抑制发生率占总人数的35．1％和8．1％，4例患者出现中性粒细胞减少性发热。Ⅲ度迟发性腹泻发生率为8．1％：结论：伊立替康联合氟尿嘧啶／亚叶酸钙双周方案（FOLFIRI）是一线治疗晚期大肠癌安全而有效的方案。

Irinotecan plus fuorouracil/ leucovorin as the first-line in treatment of 37 patients with advanced colorectal cancer

Background and purpose:Irinotecan plus fuorouracil/Leucovorin has become the standard regimen as the first-line in treating advanced colorectal cancer.We investigated the clinical response and side-effects of the first-line treatment with Irinotecan plus fuorouracil/ leucovorin(FOLFIRI) for advanced colorectal cancer.Methods:From may 2001 to march 2005,37 patients with advanced colorectal cancer were treat with irinotecan 180mg/m~(2) i.v.on day 2,and fuorouracil 400 mg/m~(2),bolus on day 1,2 and 1200 mg/m~(2),civ.44hour;leucovorin 200 mg/m~(2) i.v.on day 1,2,two weeks per cycle.Results:The response rate was 41.7%.Incidence of III/IV Grade myelosuppression was 35.1%/8.1%,and 4 patients suffered from febrile neutropenia.Incidence of III Grade delayed diarrhea was 8.1%.Conclusions:The first-line chemotherapy with a combination of irinotecan and fuorouracil/ leucovorin is effictive and well tolerated by patients with advanced colorectal cancer.